Knight Cancer signal achievements of 2022
People at the Knight Cancer Institute accomplished a lot in 2022. Through innovative, collaborative research and education, the institute delivers cancer prevention, detection, and care — one...
Tag: clinical trial
How ‘real world’ data can advance precision oncology: Q&A with Ray Bergan
There is a big gap between the narrowly focused data gathered in clinical trials and the lower-quality but more plentiful “real world" data routinely collected in clinical records, insurance claims...
Cancer researchers are reinventing clinical trials: Get the story at Knight School
The survival rate for all cancers combined more than doubled since the 1960s, a testament to the power of clinical trials that test new treatments in volunteers. But big challenges loom. Pictured...
Targeting osteosarcoma, a cancer more common in young people
Knight Cancer researchers describe positive results with the drug regorafenib. Osteosarcoma is a bone cancer that disproportionately affects teenagers, and despite substantial efforts, outcomes for...
New questions about the tradeoffs in ‘accelerated’ cancer drug studies
Cancer clinical trials that use less-reliable shortcut endpoints save relatively little time, according to an analysis of 107 cancer drugs approved for 188 indications from 2006 to 2017. Image:...
Rapid precision medicine is feasible in fight against a formidable leukemia
The Beat AML clinical trial has matched 250 study participants to targeted treatments for acute myeloid leukemia – with promising early results. Regulators were wary of the complicated study...
For military veterans with cancer, VA expands access to clinical trials in Oregon
The VA Portland Health Care System is one of 12 centers across the U.S. selected for a national initiative to give military veterans more opportunities to participate in cancer clinical trials. The...
Positive results with a targeted therapy for osteosarcoma, a cancer more common in young people
Osteosarcoma is a bone cancer that disproportionately affects teenagers, and outcomes for patients have changed little in decades. Now researchers, including two OHSU Knight Cancer Institute...
Halting resurgent prostate cancers before they spread
Q&A: Prostate cancer expert Julie Graff, M.D., explains how a new treatment option fills a void for men with resurgent tumors. When prostate cancer isn't cured by surgery or radiation, the...
An elaborate clinical trial aims a multitude of targeted therapies at one formidable cancer
A $10 million gift from The Harry T. Mangurian Jr. Foundation will help The Leukemia & Lymphoma Society expand the Beat AML Master Trial underway at the OHSU Knight Cancer Institute and other...
Cancer clinical research scholars move discoveries from lab to patients
Five oncologists at Oregon Health & Science University in Portland will receive a $25,000 salary supplement for one year, allowing them to reserve time to pursue promising research...